extract: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
4b5dedaf1d
commit
fe175a7493
4 changed files with 51 additions and 1 deletions
|
|
@ -83,6 +83,12 @@ Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF
|
|||
|
||||
BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18*
|
||||
|
||||
If GLP-1+exercise creates durable behavioral change that persists after medication stops (3.5kg regain vs 8.7kg for medication alone), then the chronic use assumption may be wrong. The optimal economic model might be time-limited GLP-1 as a catalyst for behavior change, not lifetime medication. This would dramatically reduce the inflationary cost trajectory if lifestyle support infrastructure can scale.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -71,6 +71,12 @@ Digital behavioral support may partially solve the persistence problem: UK study
|
|||
|
||||
BALANCE Model's manufacturer-funded lifestyle support requirement directly addresses the persistence problem by mandating evidence-based programs for GI side effects, nutrition, and physical activity—the factors most associated with discontinuation. This shifts the cost of adherence support from payers to manufacturers.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18*
|
||||
|
||||
Weight regain data shows that even among patients who complete treatment courses, GLP-1 alone produces 8.7kg regain vs 3.5kg for GLP-1+exercise by week 104 post-discontinuation. This means the persistence problem has two layers: patients stop taking the drug (15% continuation at 2 years), AND those who complete treatment cycles regain weight unless exercise is part of the intervention. The economic model must account for both discontinuation losses and post-treatment regain.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,25 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-combined-with-structured-exercise-achieves-substantially-better-weight-maintenance-than-medication-alone-suggesting-behavioral-change-outlasts-pharmacotherapy.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"glp-1-combined-with-structured-exercise-achieves-substantially-better-weight-maintenance-than-medication-alone-suggesting-behavioral-change-outlasts-pharmacotherapy.md:set_created:2026-03-18",
|
||||
"glp-1-combined-with-structured-exercise-achieves-substantially-better-weight-maintenance-than-medication-alone-suggesting-behavioral-change-outlasts-pharmacotherapy.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-combined-with-structured-exercise-achieves-substantially-better-weight-maintenance-than-medication-alone-suggesting-behavioral-change-outlasts-pharmacotherapy.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-18"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2026-03-01
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: review
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, lifestyle-modification, exercise, sarcopenia, muscle-preservation, adherence, weight-regain, obesity]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -75,3 +79,12 @@ Synthesis of 2025-2026 research on combining lifestyle modifications (diet, exer
|
|||
PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate)
|
||||
WHY ARCHIVED: The "exercise is the active ingredient for weight maintenance" finding significantly changes how to evaluate BALANCE model design and GLP-1 economic models under VBC
|
||||
EXTRACTION HINT: Focus on the GLP-1 alone vs. GLP-1+exercise regain comparison — this is the claim-worthy finding. Also note the BALANCE model design needs evaluation against this evidence.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- WHO December 2025 guidelines recommend GLP-1 therapies 'combined with intensive behavioral therapy to maximize and sustain benefits'
|
||||
- Meta-analysis of 22 RCTs with 2,258 participants found ~25% of GLP-1 weight loss is lean mass
|
||||
- Without exercise, 15-40% of GLP-1 weight loss is lean mass; with resistance training, lean mass loss is substantially reduced
|
||||
- Up to half of adults over 80 experience sarcopenia; aging reduces muscle mass 12-16% baseline
|
||||
- Tirzepatide may have better muscle preservation profile than semaglutide (preliminary data)
|
||||
- No FDA-approved GLP-1 compounds with proven muscle preservation claims yet
|
||||
|
|
|
|||
Loading…
Reference in a new issue